Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DMS5N4
|
|||
| Drug Name |
Adagloxad simolenin
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Triple negative breast cancer [ICD-11: 2C60-2C65] | Phase 3 | [1] | |
| Breast cancer [ICD-11: 2C60-2C65] | Phase 2/3 | [2], [3], [4] | ||
| Company |
OBI Pharma
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03562637) Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.